American Association for Cancer Research

SHERPA: Unknown

People

  1. Chandarlapaty
    Chandarlapaty
  2. Berger
    Berger
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Modi
    Modi
  6. Rosen
    Rosen
  7. Solit
    Solit
  8. Dang
    Dang
  9. Lake
    Lake
  10. De Stanchina
    De Stanchina

Groups

  1. Department of Medicine (39)
  2. Solid Tumor Oncology Division (38)
  3. Breast Medicine Service (33)
  4. GSK Faculty (27)
  5. Human Oncology and Pathogenesis Program (25)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (24)
  7. Sloan Kettering Institute Postdocs (23)
  8. Survivorship Research (17)
  9. Center for Molecular Imaging and Biotechnology (CMIB) (14)
  10. Department of Pathology and Laboratory Medicine (14)
Search Within
  1. "Jose Baselga"
Formats
  1. Meeting Abstract (102)
  2. Journal Article (36)
Groups
  1. Department of Medicine (39)
  2. Solid Tumor Oncology Division (38)
  3. Breast Medicine Service (33)
  4. GSK Faculty (27)
  5. Human Oncology and Pathogenesis Program (25)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (24)

More Groups

People
  1. Jose Baselga (138)
  2. Maurizio Scaltriti (20)
  3. Sarat Chandarlapaty (16)
  4. Maura Dickler (12)
  5. Michael Berger (12)
  6. Clifford Hudis (11)

More People

Years
  1. 2021 (1)
  2. 2020 (4)
  3. 2019 (9)
  4. 2018 (17)
  5. 2017 (11)
  6. 2016 (24)

More Years

Publications
  1. Cancer Research (109)
  2. Clinical Cancer Research (29)

Results (138)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cell line-specific network models of ER(+) breast cancer identify potential PI3Kα inhibitor resistance mechanisms and drug combinations
    Journal Article

    Zañudo, J. G. T.; Mao, P.; Alcon, C.; Kowalski, K.; Johnson, G. N.; Xu, G.; Baselga, J.; Scaltriti, M.; Letai, A.; Montero, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Oncologic therapy shapes the fitness landscape of clonal hematopoiesis
    Meeting Abstract

    Bolton, K. L.; Ptashkin, R. N.; Gao, T.; Braunstein, L.; Devlin, S. M.; Patel, M.; Berthon, A.; Syed, A.; Yabe, M.; Coombs, C.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1(E17K)-mutant, ER-positive metastatic breast cancer
    Journal Article

    Smyth, L. M.; Tamura, K.; Oliveira, M.; Ciruelos, E. M.; Mayer, I. A.; Sablin, M. P.; Biganzoli, L.; Ambrose, H. J.; Ashton, J.; Barnicle, A.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Batist, G.; Meric-Bernstam, F.; Kabos, P.; Spanggaard, I.; Lluch, A.; Schram, A.; Varga, A.; Wong, A.; Ambrose, H.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • BRCA-mediated tumorigenesis is origin and cell-type dependent
    Meeting Abstract

    Jonsson, P.; Cheng, M. L.; Bandlamudi, C.; Srinivasan, P.; Chavan, S. S.; Friedman, N. D.; Rosen, E. Y.; Richards, A. L.; Bouvier, N.; Selcuklu, S. D.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • PI3K pathway mediated splicing defects in ER+ breast cancers
    Meeting Abstract

    Ladewig, E.; Fairchild, L.; Scaltriti, M.; Leslie, C.; Toska, E.; Baselga, J.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347
    Meeting Abstract

    Iafrate, A. J.; Borger, D. R.; Vivancos, A.; Voss, M.; Cleary, J.; Meric-Bernstam, F.; Tabernero, J.; Flaherty, K.; Ishii, N.; Brichory, F.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) for early triple-negative breast cancer (TNBC)
    Meeting Abstract

    Wongchenko, M. J.; Oliveira, M.; Saura, C.; Nuciforo, P.; Calvo, I.; Andersen, J.; Coelho, J. I. P.; Gil, M. G.; Bermejo, B.; Patt, D. A.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Non-canonical, clinical ESR1 mutations promote resistance to antiestrogen therapies
    Meeting Abstract

    Toy, W.; Carlson, K. E.; Martin, T. A.; Razavi, P.; Berger, M.; Baselga, J.; Greene, G.; Katzenellenbogen, J.; Chandarlapaty, S.
    Cancer Research (2019)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: